Kamada Ltd. (TLV:KMDA)
Israel · Delayed Price · Currency is ILS · Price in ILA 2,633.00
+139.00 (5.57%)
Sep 17, 2026, 5:28 PM IDT
Kamada Revenue
Kamada had revenue of $54.92M USD in the quarter ending June 30, 2026, with 22.72% growth. This brings the company's revenue in the last twelve months to $191.85M, up 13.17% year-over-year. In the year 2025, Kamada had annual revenue of $180.46M with 12.12% growth.
Revenue (ttm)
$191.85M
Revenue Growth
+13.17%
P/S Ratio
2.52
Revenue / Employee
$415.26K
Employees
462
Market Cap
1.44B ILS
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 180.46M | 19.51M | 12.12% |
| Dec 31, 2024 | 160.95M | 18.43M | 12.93% |
| Dec 31, 2023 | 142.52M | 13.18M | 10.19% |
| Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
| Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
| Dec 31, 2020 | 133.25M | 6.06M | 4.76% |
| Dec 31, 2019 | 127.19M | 12.72M | 11.11% |
| Dec 31, 2018 | 114.47M | 11.64M | 11.32% |
| Dec 31, 2017 | 102.83M | 25.33M | 32.69% |
| Dec 31, 2016 | 77.49M | 7.59M | 10.85% |
| Dec 31, 2015 | 69.91M | -1.16M | -1.63% |
| Dec 31, 2014 | 71.07M | 442.00K | 0.63% |
| Dec 31, 2013 | 70.62M | -2.05M | -2.82% |
| Dec 31, 2012 | 72.68M | 13.19M | 22.18% |
| Dec 31, 2011 | 59.48M | 25.01M | 72.53% |
| Dec 31, 2010 | 34.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 51.58B |
| Danel (Adir Yeoshua) | 2.98B |
| Amal Holdings A.D. | 2.25B |
| Novolog (Pharm-Up 1966) | 1.81B |
| Ilex Medical | 885.35M |
| Rafa Laboratories | 459.86M |
| SofWave Medical | 310.85M |
| InterCure | 270.20M |
Kamada News
- 10 hours ago - Kamada confirms sufficient KedRAB supply amid increased demand - TheFly
- 10 hours ago - CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand - GlobeNewsWire
- 2 days ago - Kamada Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 days ago - Director David Tsur Sells 177,173 Shares of Kamada Ltd (KMDA) - GuruFocus
- 7 days ago - Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 8 days ago - Kamada Registration statement: Registration filing - Filings
- 8 days ago - Kamada files to sell $50M of ordinary shares - TheFly
- 14 days ago - Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders - GlobeNewsWire